Abstract: After consumption of plant-derived foods or beverages, dietary polyphenols such as quercetin are absorbed in the small intestine and metabolized by the body, or they are subject to catabolism by the gut microbiota followed by absorption of the resulting products by the colon. The resulting compounds are bioavailable, circulate in the blood as conjugates with glucuronide, methyl, or sulfate groups attached, and they are eventually excreted in the urine. In this review, the various conjugates from different intervention studies are summarized and discussed. In addition, the substantial variation between different individuals in the measured quercetin bioavailability parameters is assessed in detail by examining published human intervention studies where sources of quercetin have been consumed in the form of food, beverages, or supplements. It is apparent that most reported studies have examined quercetin and/or metabolites in urine and plasma from a relatively small number of volunteers. Despite this limitation, it is evident that there is less interindividual variation in metabolites which are derived from absorption in the small intestine compared to catabolites derived from the action of microbiota in the colon. There is also some evidence that a high absorber of intact quercetin conjugates could be a low absorber of microbiota-catalyzed phenolics, and vice versa. From the studies reported so far, the reasons or causes of the interindividual differences are not clear, but, based on the known metabolic pathways, it is predicted that dietary history, genetic polymorphisms, and variations in gut microbiota metabolism would play significant roles. In conclusion, quercetin bioavailability is subject to substantial variation between individuals, and further work is required to establish if this contributes to interindividual differences in biological responses.
Introduction
Quercetin is a polyphenolic compound of the flavonoid class (subclass flavonol) and is regularly consumed in the diet. Rich sources are kale, onion, various berries, apples, black tea, and red grapes Perez-Jimenez, Neveu, Vos, & Scalbert, 2010) , and also certain commercially available food supplements (Serra et al., 2012) . Quercetin safety has been critically reviewed (Harwood et al., 2007; Okamoto, 2005) and high-purity quercetin was given Generally Recognized As Safe (GRAS) status in Variability in quercetin bioavailability . . . Where information on the involvement of a specific enzyme is published (Boersma et al., 2002) , then only the most active isoforms are indicated in the figure. When the specific form is unknown, then the general notation of UGT (UDP-glucuronosyltransferase) or SULT (sulfotransferase) is used. For COMT (catechol-O-methyl transferase), LPH (lactase phloridzin hydrolase), and CBG (cytosolic β-glucosidase), only one form of the enzyme exists in humans. Information for this figure is a compilation from several publications including (Day et al., 2001; Day et al., 2000; Del Rio et al., 2013; Govind, Suiko, Sakakibara, & Ming, 2001; Hong & Mitchell, 2004) .
2000)
. Paradoxically, quercetin glycosides are generally more bioavailable than the aglycone since the latter is more insoluble in the lumen of the gut (Hollman, Devries, Vanleeuwen, Mengelers, & Katan, 1995; Hollman et al., 1996; . Since the brush border enzymes are specific for glucose, quercetin glucosides are absorbed more quickly than other types of glycosides, for example, rutin (quercetin-3-O-rutinoside), which can only be deglycosylated to quercetin aglycone by enzymes from the gut microbiota (Arts, Sesink, Faassen-Peters, & Hollman, 2004; Cermak, Landgraf, & Wolffram, 2003; Reinboth, Wolffram, Abraham, Ungemach, & Cermak, 2010; Russo et al., 2012) . The importance of solubility is apparent from studies on the bioavailability of quercetin in pigs, rats, and humans, which can be enhanced when administered in combination with a high-fat (17%) diet Lesser, Cermak, & Wolffram, 2004) , alcohol (Dragoni, Gee, Bennett, Valoti, & Sgaragli, 2006) , or with nondigestible oligosaccharides (Matsukawa et al., 2009) . After absorption by enterocytes, quercetin is glucuronidated by UDPglucuronosyl transferases (UGTs), sulfated by sulfotransferases (SULTs), and/or methylated by catechol-O-methyl transferase (COMT) present in intestinal and hepatic cells (Figure 1 ). These biotransformation reactions are also observed in rat or human hepatocytes in vitro (Vacek et al., 2012) . Once absorbed, quercetin enters the bloodstream and appears as various different chemical species, including methylated forms. In plasma, 78% to 79% was estimated as conjugates of quercetin, 10% to 13% as tamarixetin (4 -O-methyl-quercetin), and 8.5% to 11% as isorhamnetin (3 -O-methyl-quercetin) conjugates (Cermak et al., 2003; Lesser et al., 2004; Reinboth et al., 2010) . A significant proportion of conjugated flavonoids is excreted back into the intestinal lumen by enterocytes via multidrug resistance-associated protein 2 (MRP2 (ABCC2)) or breast cancer resistance protein (BCRP (ABCG2); Cermak & Wolffram, 2006) . Quercetin glucuronides serve as a more stable form of quercetin for transport in the bloodstream, but they may be deconjugated, for example, in vascular smooth muscle cells (Galindo et al., 2012; Menendez et al., 2011) and at sites of inflammation (Menendez et al., 2011; Perez et al., 2014; Shimoi et al., 2001; Yoshichika Kawai, 2014) . The conjugates themselves
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Figure 2-Schematic representation of quercetin metabolism by gut microbiota Information is taken from (Harwood et al., 2007; Lu et al., 2013; Ramesova et al., 2012; Schneider, Schwiertz, Collins, & Blaut, 1999; Serra et al., 2012; Vacek et al., 2012; Valentová et al., 2014; Walle, 2004) ; the speculative proposed intermediate where the C-ring is opened is shown in grey. R1, R2, and R3 represent substitution positions of sugars. The microbial conjugates from polyphenols are mostly found conjugated with sulfate, or sometimes glucuronide groups (Clifford, van der Hooft, & Crozier, 2013; Pimpao, Ventura, Ferreira, Williamson, & Santos, 2015) .
generally have diminished biological activity compared to the aglycone, but there are exceptions to this, and sometimes conjugated and/or methylated metabolites display biological activity distinct from that of the parent compound (Araujo, Costa, Pazini, Valadares, & de Oliveira, 2013; Beekmann et al., 2012; Lodi et al., 2009; Tribolo et al., 2008; Williamson, Barron, Shimoi, & Terao, 2005) . Quercetin derivatives, such as rutin, which are not absorbed in the small intestine, pass to the colon, where they undergo deglycosylation by α-rhamnosidases and β-glucosidases produced by the gut microbiota. The resulting aglycone is then absorbed by the colonocytes and passed into the circulation, or it is subjected to catabolic reactions to form lower-molecularweight phenolic species, as outlined in Figure 2 . Quercetin was transformed by certain strains of Pediococcus spp., Streptococcus spp., Lactobacillus spp., Bifidobacterium spp., 3, and 3, acids (Cermak, Breves, Lupke, & Wolffram, 2006) . Quercetin was also metabolized by porcine hindgut contents in vitro (Cermak et al., 2006) . After quercetin in vitro colonic fermentation with rat feces for 48 h, the main product was protocatechuic acid with lower amounts of homovanilic, phenylacetic, and p-hydroxybenzoic acids (Serra et al., 2012) . Similar degradation products were observed when quercetin was exposed to exhaustive electrochemical hydrolysis Sokolova et al., 2011 Sokolova et al., , 2012 . Degradation of quercetin by the rat gut microbiota therefore involves C-ring fission, formation of 3-(3,4-dihydroxyphenyl)propionic acid, and subsequent transformation to 3,4-dihydroxyphenylacetic acid. Further transformation leads to protocatechuic acid and then to 4-hydroxybenzoic acid. 3,4-Dihydroxyphenylacetic acid can also be dehydroxylated to m-or p-hydroxyphenylacetic and phenylacetic acids (Figure 2 ; Serra et al., 2012) . These compounds are further degraded into various simpler products and finally to carbon dioxide (Walle, 2004; Walle, Walle, & Halushka, 2001) .
The main pathways of metabolism of quercetin depend on conjugating enzymes, most of which have known genetic polymorphisms, but are also inducible by drugs, food, and the environment. Quercetin catabolism is also affected by the microbiota composition, which is influenced by multiple factors. It is not surprising, therefore, that there is substantial interindividual variation in absorption and metabolism of quercetin between individuals. This has been observed for other groups of polyphenols. For example, the metabolism of ellagitannins in humans shows several metabolizing phenotypes, or "metabotypes" (Gonzalez-Sarrias et al., 2017) . These phenotypes are determined by the concentration and activity of intestinal carriers and postabsorptive phase I and phase II metabolizing enzymes, and also by the composition and activities of the gut microbiota, many of which will be influenced by the genotype of the subject (Yousri et al., 2014) . Pharmacogenomic studies have demonstrated that, for some drugs, individuals Variability in quercetin bioavailability . . . can be categorized into poor, intermediate, or extensive absorbers or metabolizers, and dosing has to be adapted clinically (Kaddurah-Daouk, Weinshilboum, & Pharmacometabolomics Research Network, 2014) . Plant food phytochemicals are absorbed and metabolized through the same polymorphic carriers and enzymatic systems as drugs, and so their pharmacokinetics are also likely to depend on the same determinants.
In this review, we have examined interindividual variation in quercetin bioavailability by systematically assessing published human studies dealing directly or indirectly with this subject. Bioavailability has several definitions, but it is generally regarded as representing the amount of a substance that reaches a given site of action. For polyphenols, this is usually considered as the amount which appears in plasma. The minimum bioavailability can also be estimated as a percentage of dose based on urinary measurement of the compound and its metabolites Pérez-Jiménez et al., 2010) . A comparable term is ADME (absorption, metabolism, disposition, and excretion), which can be applied to polyphenols but is more often used in the pharmaceutical area (Prot et al., 2014) . Here, the term bioavailability is used for convenience but is used in a relative sense so that different sources and different derivatives can be compared (Rescigno, Thakur, & Marzo, 1994; Schlemmer, 1995) .
Assessment of the Literature for Studies on Quercetin Bioavailability
In order to find as many papers as possible and remove any bias, we performed a systematic search for papers on flavonol bioavailability in humans, and then further refined it by examining each paper for data on interindividual variation. The search was conducted using Web of Science and PubMed to include all original research articles written in English, published between January 1990 and March 2015, on the relationship between interindividual variation and quercetin ADME in humans. The search strategies were as follows: "(quercetin OR kaempferol) AND human AND (bioavailability OR absorption) AND (in vivo OR clinical OR intervention OR volunteer) NOT review" and 298 abstracts were retrieved. Updated searches were performed in March 2016 and July 2017 and there retrieved 20 and 25 additional abstracts, respectively. Kaempferol was originally included as it is also a flavonol, but since no relevant papers on interindividual variation in absorption were ultimately found, it was not considered further in this review. In phase 1, all studies identified by the search strategy were randomly split within reviewers. Based on the title and abstract, only studies that were associated with ADME parameters from human intervention studies with quercetin or quercetin food sources were kept for phase 2 of the data collection process. In vitro, animal studies, and human intervention studies that evaluated the impact of quercetin on the pharmacokinetics of other compounds were excluded. In phase 2, the remaining studies, based on their abstracts, were again randomly split and distributed to authors and data from the papers were summarized in a tabulated form. In order to standardize reporting of differences between individuals in the various studies, the data presented was further processed and made more consistent where necessary and possible. The literature search of human intervention studies in phase 1 on quercetin and quercetin-rich foods resulted in a total of 343 potential publications for inclusion. A review of titles and abstracts reduced the number of relevant publications to 97, and, after screening the full publications according to predefined criteria, 55 articles met the inclusion criteria and were included in this review (Figure 3 ). 
Design of Human Intervention Studies Examining Quercetin Bioavailability
Papers on the absorption by volunteers of quercetin from raw foods, processed foods, and food extracts, or from quercetin in solution, powder, tablet, or capsule form, were included. Studies were divided by source of quercetin as follows: food (29 studies, Table 1), pure quercetin or its glycosides (17 studies, Table 2 ), mixed matrix of food with pure compounds (six studies, Table 3 ), or food extracts (three studies (data not shown); Correa et al., 2014; Schulz, Schurer, Bassler, & Weiser, 2005; Wojcicki et al., 1995) . In general, bioavailability was estimated by measuring quercetin derivatives or catabolites in blood or urine. Since quercetin is mostly found in several conjugated forms in vivo (Figure 1 ), then the analytical procedure followed by most authors is to either attempt to measure as many of the conjugated forms as possible, or to hydrolyze the samples to give quercetin and/or methylated quercetin in the aglycone form, and then measure just the resulting aglycone forms. Thirty-five studies estimated quercetin absorption by measuring quercetin aglycone after hydrolysis, 12 studies estimated quercetin conjugates, and five studies reported measuring both conjugates and aglycone after hydrolysis in urine and/or plasma. The number of subjects, however, was usually relatively small (<10).
Interindividual Variations in Quercetin Bioavailability in Studies without Explicit Individual Data
Most studies on quercetin bioavailability present the data as concentrations in plasma or urine. The data, over time, are then used to estimate pharmacokinetic parameters such as c max (the maximum concentration reached), T max (the time at which c max is Cooked onion slices Variability in quercetin bioavailability . . . (Wilms, Hollman, Boots, & Kleinjans, 2005) Fruit juice (black currant and apple juice) 3 weeks Cross-over, repeated 1 week interventions separated by 2 weeks 750, 1000, and 1500 mL (4.8, 6.4, and 9.6 mg quercetin/days) 5 (4 F) Plasma and urine Hydrolysis (Young et al., 1999) Tomato puree Variability in quercetin bioavailability . . . (Petersen et al., 2016) apparent), and the area under the curve (AUC) for each individual chemical species, and often the data are shown as concentration versus time curves. Most studies present the mean value of all of the volunteers together with a value for standard deviation, standard error of the mean (SEM) or percentage coefficient of variation (% CV), and do not explicitly present data on individuals. Where not presented, the % CV was calculated using the standard deviation (SD) or SEM by the formula CV = 100 × SD/mean, and SEM was converted to SD by the formula SD = SEM × Ýn, where n is number of volunteers. To provide an illustration of how the % CV and the interindividual variation are related, theoretical data are used to demonstrate the relationship between typical interindividual variation and a calculated % CV in Figure 4 . This should allow the reader to grasp what a % CV means in terms of person-toperson variation in any measured parameter. Real published data from studies on quercetin given to volunteers are shown in full in Table 4 to 6. For analysis of interindividual variation in plasma, we have only included studies where c max and AUC values were presented, or could be calculated based on the data provided in the original paper. Because of the heterogeneity in quercetin sources in the studies with quercetin-containing foods (see Table 1 ), only variability in studies with onion-derived products were chosen to allow a more appropriate comparison. For most of the studies with onions, where the quercetin glucosides present are absorbed in the small intestine, and for pure quercetin glucosides, the CV for c max for onions ranged from 38% to 48% (Table 4) , and for quercetin glucosides from 34% to 45% (Table 6 ). For glycosides other than glucosides, the CV values appear higher: c max CV was 58% to 80% (Table 6 ). This suggests that the % CV could be lower when the site of absorption is the small intestine compared to when it occurs in the colon (including the action of the microbiota). Although these data are far from conclusive, we can hypothesize that compounds which undergo microbial metabolism in the colon exhibit a greater interindividual variation than compounds absorbed in the small intestine. This hypothesis could be tested systematically for quercetin in the future and in addition could apply to other compounds. The work of Graefe et al. (2001) follows the same trend and is consistent with this hypothesis, but all of the values for c max are higher than those from the other papers (see Table 4 and 6). When given as aglycone, quercetin absorption is highly dependent on solubility within the gastrointestinal tract. The proportion of quercetin which is solubilized will be absorbed in the small intestine, but the fraction of quercetin which is out of solution will not be absorbed and will pass to the colon; part will be absorbed at that site after microbe-catalyzed deglycosylation, but part will be catabolized by the gut microbiota into lower-molecular-mass compounds. With administration of quercetin as a pure compound, the interindividual variation (CV) in c max ranged from 29% to 54%, which is similar to the above values for absorption from the small intestine for food. These data, therefore, imply that the extent of interindividual variation is not dependent on food or supplement source, provided that the chemical form is the same in each tested food or supplement.
Pathways of Quercetin Conjugation and Metabolism
Many conjugates and catabolites from quercetin in humans have been identified. Most of the studies considered here focused on the concentration of quercetin and potentially also of isorhamnetin and tamarixetin in samples (plasma, urine) treated by deconjugating enzymes (usually crude β-glucuronidase/sulfatase from Helix pomatia) or submitted to acidic hydrolysis Theoretical maximum plasma concentration c max data (mean c max = 100) were calculated for 10 volunteers to allow a CV of 10%, 50%, and 90% to be calculated using the "STDEV" function of the spreadsheet in the Microsoft Excel program. The x-axis shows the "volunteer number" and the mean value (av) was set to 100%. Error bar shows the standard deviation in the average values of volunteers 1 to 10. With a CV of 90%, the data appears to stratify between "responders" and "nonresponders." Table 4 -Coefficient of variation in pharmacokinetic parameters when raw and cooked onions were administered and quercetin was measured after hydrolysis (derived from the studies shown in Table 1 a Calculated for the parameters with available mean and SD or SEM data. b Calculated for 3 different doses at upper and lower CI using the formula SD = |Mean-CI|/z × Ýn with z = 1.96 and 1.65 for 95% and 90% CI, respectively, and expressed as mean, n = 6 (3 doses, 2 lower and upper interval (Day et al., 2001; Murota et al., 2010) . Identification of the exact position of conjugation is, in most cases, impossible without authentic standards with known exact structure, as confirmed by nuclear magnetic resonance.
During catabolism by the microbiota in the colon, C-ring fission is the predominant reaction in quercetin degradation. Subsequent products can then be absorbed by the colon epithelial cells, conjugated by mammalian phase II enzymes, and then Variability in quercetin bioavailability . . . ultimately be excreted in the urine, or, alternatively, a proportion may not be absorbed and then appear directly in the feces. Significant increases in urinary concentrations of 4-ethylphenol, benzoic acid, and 4-ethylbenzoic acid were noted in healthy men after oral consumption of 200 mg of pure quercetin (Loke et al., 2009 ). After supplementation with quercetin-3-O-rutinoside, phenylacetic acids, namely, 3-hydroxyphenylacetic acid (36% of the dose ingested), 3-methoxy-4-hydroxyphenylacetic acid (8%), and 3,4-dihydroxyphenylacetic acid (5%) were excreted into the urine of healthy humans. The absence of a conventional microbiota, as in ileostomist subjects, abolished the formation of the majority of the phenolic acid metabolites, indicating the importance of bacterial biotransformation in the formation of these compounds (Olthof, Hollman, Buijsman, van Amelsvoort, & Katan, 2003) . Table 7 summarizes qualitatively all of the studies where the presence of a metabolite is reported or has been definitely identified as absent. The most commonly identified conjugates where a single moiety has been added are quercetin-3 -O-sulfate, quercetin-3-O-glucuronide, and quercetin-3 -O-glucuronide. Quercetin was also methylated and glucuronidated, forming isorhamnetin-3-O-glucuronide and isorhamnetin-4 -Oglucuronide, but it appears that methylation prevents subsequent sulfation and vice versa. Quercetin can also be doubly substituted with both sulfate and glucuronide groups; and in some papers detection of methylated quercetin which has been diglucuronidated was reported. There is also some evidence for quercetin substituted with both a glucose and a sulfate or glucuronide, but it is not clear if a small amount of quercetin was absorbed in the form of a glucoside and then further conjugated, or if the glucosylation occurred postabsorption (Mullen et al., 2004 . Some microbial metabolites of quercetin were identified when rutin was given in pure form or in tomato juice, and these include phenylacetic and hydroxyhippuric acid derivatives (Jaganath, Mullen, Edwards, & Crozier, 2006; Olthof et al., 2003) . Quantitative data on the presence of quercetin conjugates and microbial metabolites are given in Table 8 . Some metabolites such as quercetin-3 -O-sulfate are found only in plasma and not in urine, whereas many conjugates are found in both urine and plasma.
Assessment of Individual Papers Where Data on Interindividual Variation are Specifically Presented
Specific information on the inter-or intraindividual differences in quercetin bioavailability was available from 10 studies. Of these, 6 show the data in graphical form only (Boyle et al., 2000; Boyle, Dobson, Duthie, Kyle, & Collins, 2000; Davalos, Castilla, GomezCordoves, & Bartolome, 2006; Loke et al., 2009; Moon, Wang, DiCenzo, & Morris, 2008; Petersen et al., 2016) , one presents results based on radio-scintillation counting (Walle et al., 2001) and only three provide numerical quantitative data for individual volunteers (Ferry et al., 1996; Jaganath et al., 2006; Moon, Nakata, Oshima, Inakuma, & Terao, 2000) . The form of presentation differs substantially for each of these publications, which are discussed below. To be consistent in this part, all original values for C max , AUC and amount in urine were converted to nM, nM.h and nmol, when necessary.
Uptake of quercetin from food was evaluated in six healthy nonobese normocholesterolemic nonsmoking female volunteers in a randomized 2-phase cross-over single-dose supplementation trial using a meal of fried onions (200 g, phase 1) or fried onions (200 g) with fresh cherry tomatoes (100 g, phase 2, Boyle et al., 2000; Table 1 ). Wash-out periods of 7 days were controlled by a validated food questionnaire and weighed intake record, and plasma concentration of quercetin confirmed compliance. Predominant flavonoids present in plasma were identified as "quercetin-3-glucoside" and "isorhamnetin-3-O-glucoside" by HPLC with UV and fluorimetric detection, but they were more probably glucuronides since the authors did not have the appropriate glucuronide standards at the time. Interindividual variation in the extent of "quercetin-3-O-glucoside" (that is quercetin-3-O-glucuronide) absorption into plasma, and also the time at which the highest concentration was present in the plasma, was observed. Individual data for plasma concentration for two main flavonols in plasma are presented as bar graphs at time points -24, 0, 4, 8, and 24 hr for the 1st phase only, and the difference between the highest and lowest responder at 4 hr after ingestion can be estimated as approximately one order of magnitude (about 20 compared with 300 nM). In the 2nd phase, total plasma concentration of quercetin measured in hydrolyzed samples was presented as mean ± SEM with CV 24%. This study also evaluated oxidation-stress-related plasma markers, but these were displayed as mean ± SEM only and thus cannot be related to plasma levels of quercetin.
Individual plasma quercetin concentration-time profiles for 10 individuals after 7 days of supplementation with 500 mg quercetin in capsule form three times daily (measured for 8 hr over the last day of the supplementation period) were published separately together with numerical data as means, medians, and range (Moon et al., 2008;  Table 2 ). This study differs from all others in that no baseline level was presented in the paper and no dietary restriction or wash-out was applied for the (pre-) supplementation period, although ingestion of "quercetin products" within 30 d was an exclusion criterion. The study focused on reentry pharmacokinetics, and it is clear that some subjects showed reentry peaks of quercetin conjugates and others did not. The absorption rate constant and bioavailability also showed high interindividual variability. From the individual plasma profiles, two subjects can be assigned as low responders (plasma concentration ࣘ 3 nM throughout the measurement period), and at least five as high responders (peak concentration ࣙ 25 nM). Peak concentrations of quercetin aglycone and conjugated metabolites varied from 1.6 to 132.1 and 533 to 4000 nM, respectively. No determinants for the variability observed are available. Individual plasma profiles of quercetin concentration were presented also for a pharmacokinetic study with rutin (Boyle et al., 2000; Table 2 ). In this case, however, the profiles were measured in only three female volunteers following a single dose of 500 mg rutin. Subjects showed different kinetics, with two having maximal plasma level at 7 hr and the third at 4 hr. The extent of absorption varied between 130 and 730 nM and the rate of clearance was also highly variable. The authors then performed a 6-week placebo-controlled supplementation study (n = 8 in each group, 500 mg rutin/d). While the plasma levels of quercetin, kaempferol, and isorhamnetin before and after the study were presented as bar graphs using means and SEM, individual bar graphs are available for plasma "total phenols" (using the Folin-Ciocalteu assay) at weeks 1 and 5. In this case, there was no clear high or low responder, with the range between ß11 and 15 μg/mL.
Data were presented individually for 12 healthy men using line graphs for plasma and urinary total quercetin before, and 2 or 5 hr after supplementation with a single dose of 200 mg quercetin in a cross-over design including the control but also (-)-epicatechin and (-)-epigallocatechin gallate (EGCG, 1 week wash-out between treatments, Loke et al., 2009 ; Table 2 ). There Jaganath et al., 2006) a In ref (Lee et al., 2012) , quercetin-3-O-sulfate was reported, but this is likely to be a typographical error since the authors themselves give the structure of quercetin-3 -O-sulfate. Variability in quercetin bioavailability . . . were apparently high and low responders (four subjects with 4-to 5-fold increase and at least two subjects with a slight increase). More importantly, this study also evaluated 11 aromatic phenolic compounds that increased significantly in the urine of the participants, probably catabolites from flavonoid microbial degradation. Unfortunately, these data are not presented individually, and, therefore, we cannot conclude if low response in plasma or urine quercetin concentration is related to the (increased) level of microbial metabolites. However, significant increases occurred in urinary excretion of 4-ethylphenol (increased in 100% of participants), benzoic acid (83%), and 4-ethylbenzoic acid (83%), which all significantly correlated with the changes in plasma and urinary total quercetin. Moreover, 67% of the participants showed increased urinary excretion of 2-methoxyphenylacetic acid and 3-phenylpropionic acid, and 58% for 3-(4-hydroxyphenyl)-propionic acid (Loke et al., 2009) . A similar form of data presentation using line graphs was chosen also for a parallel singletreatment supplementation study with grape juice (n = 14) and fried onions (n = 2), but for quercetin plasma level at 0 and 2 hr in placebo (n = 6) and grape juice treatment groups only (Davalos et al., 2006 ; Table 1 ). The limitation of this study is a high baseline level of quercetin (there was only a 24-hr "wash-out" before the intervention during which the volunteers were "advised" to refrain from quercetin containing food, with no compliance control) and also a very low number of subjects in the onion group. A decrease in plasma quercetin level from ß130 to 80 and 50 nM was observed in two volunteers from the placebo group. In the grape juice group, seven subjects displayed no increase in plasma quercetin and there was only one relatively high responder (2-fold increase). Mean plasma concentration was 46 nM with SD 20 nM (CV 43%). This might be related to very low quercetin intake (4.9 mg) from the grape juice or measurement too early after administration. Bioavailability of quercetin from four different sources (apple peel, vacuum-impregnated apple chips, apple peel extract capsules, and quercetin dihydrate capsules, all providing 71 μmol of quercetin equivalents) was investigated in six healthy subjects (Petersen et al., 2016;  Table 3 ). This single dose, diet-controlled, cross-over study had 1-week wash-out periods before the study and between each treatment. The compliance seems to be satisfactory with no measurable quercetin and total flavonols at baseline (Ferry et al., 1996) . AUC values obtained by pharmacokinetic modeling for all 14 patients (each patient represented by a filled circle) for the tested doses of quercetin administered by intravenous (i.v.) injection (AUC data normalized to nM × h).
(estimated from plasma concentration curves). Plasma pharmacokinetic parameters and quercetin plasma concentration curves were presented as mean ± SEM, but individual AUC 0-24 h values were also shown in graphical form (bar graphs) separately for each treatment. Individual response varied substantially and allowed the authors to divide the participants into subgroups of high and low responders, with the difference in AUC being up to 10-fold higher in the highest responder compared with the lowest (estimated from the bar graphs (Petersen et al., 2016) .
Absorption and disposition of 14 C-radiolabeled quercetin was studied in six healthy subjects after oral and intravenous (i.v.) administrations (Walle et al., 2001 ; Table 2 ). Data are presented individually, but also as mean ± SEM. The main limitation of this study is that quercetin was 14 C-labeled only on the C-4 position of the C ring. Although this was a cross-over study, only 4 subjects followed both oral and intravenous treatment, and recovery in the exhaled air after both treatments was available for only 1 volunteer. On the other hand, radioactivity was measured not only in urine and plasma, but also in feces and expired air, with individual volunteer data presented in a tabulated form. The CV calculated in this study was ß27 and 14% for AUC (37 to 68 and 0.30 to 0.37 μmol.h/L for oral and intravenous dose, respectively) and 21% and 18% for radioactivity recovery from urine (3.3% to 5.7% and 18.4% to 26.8% for oral and intravenous dose, respectively). A large variability was found for the recovery of radioactivity from exhaled air. In some individuals, 14 CO 2 started to appear 4 hr after administration and in others not until 8 hr and, therefore, 14 CO 2 in the expired air represented 23.0% to 81.1% of the radioactivity administered. Taking into account the limitations of this study, 2 volunteers can, however, probably be classified as relatively high responders (AUC 65.5, 68.0 and 0.37, 0.39 μmol.h/L for oral and intravenous doses, respectively; urine recovery 5.4%, 5.7%, and 20.1, 19.7%), but recovery as 14 CO 2 is known for intravenous dose only and differs markedly (81.1% and 25.5% of the radioactivity administered; Walle et al., 2001) .
Quercetin concentration in human plasma from seven volunteers was determined before and after a short-term ingestion of onions (Moon et al., 2000;  Table 1 ). The subjects were given diets containing onion slices (67.6 to 93.6 mg of quercetin equivalents/d) with meals for 1 week. After 10 hr of fasting, quercetin was measured in plasma after β-glucuronidase-sulfatase treatment, and the concentration increased on average 16-fold after the 1-week trial. However, individual data again indicated a substantial variation between volunteers, some with a very low response (8-fold, calculated from data) compared to others with a higher response (27-fold, calculated from data). In a Phase I clinical trial, quercetin was administered by short intravenous infusion at escalating doses at 3-week intervals in cancer patients (Ferry et al., 1996;  Table 2 ). Quercetin pharmacokinetics were measured during the first 3 hr at frequent intervals, and individual plasma profiles were plotted for seven tested doses in seven different patients. By analyzing the curves, it is clear that the patients responded differently to quercetin administration. For example, one patient given a dose of 630 mg quercetin/m 2 showed, after 120 min, a circulating blood level of quercetin lower than a patient on 200 mg/m 2 . This variation is also reflected in the parameters calculated by pharmacokinetics modeling for 14 patients (shown in Figure 5 ). For seven patients treated with 945 mg quercetin/m 2 , the mean amount of quercetin excreted in urine ranged from 0.03% to 7.6% of the dose administered, also indicating a considerable interpatient variability. In this study, quercetin levels were determined after intravenous injection, which eliminates variables derived from microbiota and intestinal absorption, suggesting that variations in quercetin-metabolizing enzymes and transporters contribute highly to interindividual variability.
In order to study the contribution of the small and large intestine to the absorption and metabolism of rutin in humans, a study was conducted with a single dose of tomato juice containing rutin (176 μmol) by healthy volunteers and ileostomists (Jaganath et al., 2006;  Table 1 ). Quercetin-3-O-glucuronide and isorhamnetin-3-O-glucuronide were absent at baseline, and were measured at 4, 5, 6, 7, and 8 hr postingestion. The authors noted a high extent of variation between the volunteers, and also for excretion of urinary metabolites. Over a 24-hr period, one of the volunteers excreted a total of 4981 nmol of metabolites corresponding to 2.8% of the ingested dose of rutin. In contrast, excretion by the other subjects ranged from 40 to 608 nmol, equivalent to 0.02% to 0.35% of intake. The lower level of excretion of rutin metabolites Variability in quercetin bioavailability . . . by volunteers was limited to isorhamnetin-3-O-glucuronide and the 3-, 3 -, and 4 -glucuronides of quercetin. The authors concluded that this large interindividual variation, either in plasma or urine, may be related to the dependency of rutin metabolism on the microbiota. The low urinary recovery of the ingested rutin as glucuronides, glucosides, and methylated metabolites of quercetin, and identification of low molecular weight phenolic acids metabolized by microbiota, suggest that the latter may account for the most significant proportion of the metabolism of rutin/quercetin. No individual data were presented for the lowmolecular-weight phenolic acids, but CV for total levels of excretion varie from 24% for 4-hydroxyhippuric acid to 77% for 3-methoxy-4-hydroxyphenylacetic acid (estimated). Importantly, this study highlights that an individual who would be considered a low responder, as judged by evaluating glucuronides, glucosides, and methylated metabolites of quercetin, may actually be revealed as a faster metabolizer and therefore higher responder when assessed by the concentration of low-molecular-weight phenolic acids. This emphasizes that a precise understanding of interindividual variability of quercetin bioavailability requires measurement of all metabolic routes, including the gut microbiota.
Factors Affecting Interindividual Variation in Quercetin Bioavailability
The present paper clearly indicates that a substantial interindividual variability in quercetin bioavailability was observed in all studies. Given the complexity of the pathways of metabolism, which is obvious from Figure 1 and 2, interindividual variation in quercetin metabolism can arise from numerous factors. These can include, but are not limited to, genetic polymorphisms, dietary adaptation, composition of gut microbiota, drug exposure, and other subject characteristics such as body mass index (BMI) and health status. There are several genetic polymorphisms in the enzymes and transporters, shown in Figure 1 , which could account for some variability. Polymorphisms have been reported for LPH (Flatz & Rotthauwe, 1977) , UGTs (Sugatani, 2013) , COMT (Ding, Fu, Chen, & Wang, 2010) , SULTs (Glatt et al., 2000; Rossi et al., 2004) , ABC transporters (Kerb, Hoffmeyer, & Brinkmann, 2001) , and organic anion transporters (OAT, Fujita et al., 2005) . However, to date, none of the studies have examined the contribution that these polymorphisms might make to quercetin metabolism in vivo. In addition, many of these enzymes and transporters are modulated by diet, drugs, and environment, adding an additional layer of complexity.
Conclusions and Future Recommendations
An important and probably the most essential question, which has not yet been addressed, is the presence of any link between bioavailability and bioefficacy. Such a study would address the hypothesis: Does a high absorber of quercetin also show a greater biological response to quercetin? This is complicated by the gut microbiota, and one could equally ask the question: Does the presence of high quantities of microbial metabolites correlate with a more pronounced biological response? Recently, the role of interindividual variability on the impact of flavonols on cardiometabolic biomarkers was investigated, but owing to the lack of data effects could not be correlated with bioavailability (Menezes et al., 2017) .
Further studies designed specifically to address interindividual variation are needed. At least moderately larger (n ࣙ 20) studies presenting individual data for the pharmacokinetics of quercetin (and glycosides occurring in foods), including parent compound and best-known low-molecular-weight metabolites, together with details about the study subjects such as age, gender, genotype, composition of gut microbiota, diet, life style, and health status are necessary to address this knowledge gap in the future. Ideally, this information would be coupled with bioactivity and biomarker measurements. The most important aspect for future studies to consider, but in some ways the most difficult to address, is to determine whether a "low responder" exhibits a smaller response in a health biomarker compared to a "high responder."
